Skip to main content

In vivo generation of Chimeric Antigen Receptor cells to treat hemopoietic malignancies

Ronald Levy

Ronald Levy


Board of Trustees of the Leland Stanford Junior University

Project Term: July 1, 2020 - June 30, 2023

This project is aimed at investigating a pre-clinical “off-the-shelf” CAR (chimeric antigen receptor) T-cell immunotherapy approach where the CAR cells are generated directly in the patient’s body. Importantly, this product will be a truly off the shelf therapy that is ready instantaneously and can be used repeatedly without the restriction of time-consuming manufacturing processes.

Lay Abstract

We aim to develop a novel, off-the-shelf Chimeric Antigen Receptor (CAR) therapy for leukemia and lymphoma. While the promise of CAR T-cell therapy it takes weeks to prepare CAR T cells. We propose a solution to this problem by utilizing a newly developed mRNA delivery platform to generate CAR cells in the body without having to engineer the cells outside the body.

This Discovery award is sponsored through a partnership between LLS, the Mark Foundation for Cancer Research and The Paul G. Allen Frontiers Group.

To All Projects